Over the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...

What is evident in the last few trading sessions is how the street is treating Q4 earnings numbers. If a company delivers in terms of numbe...

The markets should be in a happy frame of mind till the time the current ceasefire in the Gulf region holds. Not many may like us using the...

Sunil Singhania backed Abakkus Mutual Fund has unveiled the maiden portfolio of its smallcap fund - Abakkus Small Cap Fund, following an in...

Sanofi Consumer Healthcare shares surged over 14% following a robust 50% year-on-year net profit increase to Rs 66.5 crore in Q4. Driven by...

Emcure Pharmaceuticals and Sanofi India have announced a distribution agreement. Emcure will promote Sanofi India's oral anti-diabetic prod...

Shares of Sanofi Consumer Healthcare India made their market debut on Friday, listing on both the NSE and BSE. On its first day of trading,...

Drug firm Sanofi India on Wednesday said its board has approved the demerger of its consumer healthcare business into a separate entity. Th...

A Sanofi spokesperson told ET that a glut of supplies added during Covid-19 and the struggle to win contracts from Unicef for its critical ...

Hrosz will transition from being Sanofi’s general manager, Consumer Healthcare business in Brazil to his new role in India as soon as the a...

Sanofi India’s counter fell to a low of Rs 7,159 as against the previous close of Rs 7,280.40 on the National Stock Exchange.

The Germany-based BioNTech will initially produce the vaccines at Sanofi facilities in Frankfurt, starting in the summer, according to a Sa...

Sanofi, which made $38.8 billion of sales in 2018, is a major manufacturer of vaccines, insulin, cancer treatments and cardiovascular drugs.

In a statement Sanofi-aventis said its offer of $69 per Genzyme share was extended till February 15 midnight.

Sanofi-aventis has a significant presence in India. Last year, Sanofi-aventis had sought to acquire an 80pc stake in ShanthaBiotechnics for...

Biotech firm Genzyme Corp. says its board of directors is rejecting Sanofi-Aventis SA's $69 a share offer and recommending Genzyme sharehol...

French drug maker Sanofi-Aventis is likely to make an formal offer to acquire US-based biotech company Genzyme for USD 19 billion, says a m...